Background: Based on their in vitro effects, ZIP and chelerythrine have been used as PKM inhibitors and staurosporine as a negative control to implicate PKM in memory. Results: ZIP and chelerythrine do not and staurosporine does inhibit PKM in cells and brain slices. Conclusion: Cellular pharmacology of PKM contrasts with its in vitro profile. Significance: Contrary to current dogma, PKM may not mediate memory.
A number of recent studies have used pharmacological inhibitors to establish a role for protein kinase M (PKM) in synaptic plasticity and memory. These studies use zeta inhibitory peptide (ZIP) and chelerythrine as inhibitors of PKM to block long term potentiation and memory; staurosporine is used as a negative control to show that a nonspecific kinase inhibitor does not block long term potentiation and memory. Here, we show that neither ZIP nor chelerythrine inhibits PKM in cultured cells or brain slices. In contrast, staurosporine does block PKM activity in cells and brain slices by inhibiting its upstream phosphoinositide-dependent kinase-1. These studies demonstrate that the effectiveness of drugs against purified PKM may not be indicative of their specificity in the more complex environment of the cell and suggest that PKM is unlikely to be the mediator of synaptic plasticity or memory.
Synaptic plasticity is generally thought to be the cellular correlate of memory (1) . In particular, long term potentiation (LTP) 6 of synaptic transmission, which is triggered by a brief high frequency activation of synapses, is commonly thought to account for the maintenance of memory. Research directed toward understanding the molecular basis of LTP and memory has firmly established the role of such molecules as synaptic NMDA receptors and such processes as a rise in intracellular calcium in triggering synaptic plasticity (1) . Subsequent biochemical events, especially those that maintain LTP and memory, however, have not been well established. One proposal has been that the transient rise in intracellular calcium leads to production of a brain-specific alternative transcript of protein kinase C (PKC) that encodes only the catalytic domain (PKM) (2) . This persistently active enzyme could phosphorylate downstream activators and maintain plasticity and memory beyond the initial triggering events (3) (4) (5) (6) (7) .
Evidence that PKM is required for LTP and for the maintenance of several forms of memory has depended almost exclusively on the use of pharmacological approaches (3) (4) (5) (6) (7) . These studies have relied on the use of zeta inhibitory peptide (ZIP), a myristoylated putative PKC-inhibiting peptide derived from the autoinhibitory pseudosubstrate peptide sequence within PKC, chelerythrine, an apoptosis-inducing compound that is marketed, and extensively used, as a PKC inhibitor (8, 9) , and staurosporine, a general protein kinase inhibitor (10) . ZIP and chelerythrine have been found to block LTP and memory, theoretically by inhibiting PKM, whereas staurosporine, which does not inhibit purified PKM in vitro, fails to do so. Beyond their in vitro testing against pure protein, however, the effectiveness of ZIP or chelerythrine and the ineffectiveness of staurosporine in inhibiting PKM within the complex milieu of mammalian cells and tissues have never been established. Indeed, studies show that the cellular effects of chelerythrine are not mediated by PKC (11) , nor does the compound inhibit PKC isoforms (or any other kinase in a screen of 34 structurally diverse kinases) in vitro (12, 13) or in cells (14) . Furthermore, the effectiveness of pseudosubstrate peptides in binding and inhibiting an enzyme depends largely on their intramolecular nature, an advantage not possessed by ZIP. And lastly, staurosporine, though it may not inhibit PKM directly in vitro (3, 15) , does inhibit phosphoinositide-dependent kinase-1 (PDK1) (10, 16) , the upstream kinase whose constitutive phosphorylation of all PKC isoforms is required for their kinase activity (17) (18) (19) . The discrepancies between the potential effectiveness of these compounds in inhibiting PKM activity in cells and their reported effects on learning and memory suggest that PKM is not mediating the effects of these drugs in cells.
Here, we examine whether the inhibitors used to implicate PKM in learning and memory block PKM activity in the context of heterologous cells and brain slices. We demonstrate that those inhibitors that have been reported to impact learning and memory, ZIP and chelerythrine, do not inhibit PKM in cells, whereas an inhibitor reported not to impact learning and memory, staurosporine, does inhibit PKM in cells. These data indicate that PKM is not the cellular target of ZIP or chelerythrine, that PKM is a cellular target of staurosporine, and that PKM likely does not mediate learning or memory.
EXPERIMENTAL PROCEDURES
Materials-ZIP and scrambled ZIP were obtained from AnaSpec and dissolved in PBS obtained from Cellgro. Chelerythrine, staurosporine, and bisindolylmaleimide IV (bisIV) were obtained from Calbiochem and dissolved in DMSO obtained from Sigma. Ser(P) PKC substrate antibody was obtained from Cell Signaling. Phospho-MARK2 antibody was obtained from Abcam. DsRed antibody, which recognizes DsRed variants including mRFP and tdTomato, was obtained from Clontech. ␤-Actin antibody was obtained from Sigma. An antibody that specifically recognizes the phosphorylated activation loop of PKC isozymes (pAL) was characterized previously (17) .
Plasmids-The C kinase activity reporter (CKAR) construct was described previously (20) . PKM constructs consist of monomeric RFP fused to the C terminus of the last 409 amino acids of rat PKC. Mammalian PKM-RFP and mRFP vector control constructs were cloned into pcDNA3. Sindbis viral PKM-RFP and tdTomato vector control constructs were cloned into pSinRep5, and Sindbis virus was prepared as described previously (21) .
Cell Culture and Transfection-293T, HeLa, and COS-7 cells were maintained in DMEM (Cellgro) containing 5% FBS (HyClone or Invitrogen) and 1% penicillin/streptomycin (HyClone) at 37°C in 5% CO 2 . Transient transfections were carried out using FuGENE 6 (Roche Applied Science) or jetPRIME (VWR International) ϳ24 h after cells were plated. Inhibitor treatments and cell lysis were performed ϳ24 h and imaging experiments 48 h after transfection.
Brain Slices and Infection-Organotypic hippocampal brain slice cultures were prepared as described previously (22) from postnatal day 6 -7 rat pups. Cultures were maintained for 7-9 days before slices were injected with Sindbis virus containing either tdTomato vector control or PKM-RFP. Cells were allowed to express for 24 h before the brain slices were incubated with inhibitors for 4 h, and two brain slices per group were combined and homogenized on ice by sonication in 300 l of radioimmunoprecipitation assay buffer containing 2% protease inhibitor mixture (Roche Applied Science) and 20% phosphatase inhibitor mixture (Calbiochem). Lysates were then cleared by centrifugation at 16,000 ϫ g at 4°C. Protein concentrations were determined using a BCA assay (Thermo Scientific) to determine loading for Western blotting.
Immunoblotting-293T and HeLa cells were plated in 6-well plates, transfected with either mRFP or PKM-RFP, and grown to confluence. Cells were treated with inhibitors for 1 h in cell culture medium at 37°C and washed with ice-cold PBS. Cells were then lysed on ice in a buffer containing 1% Triton X-100, 50 mM Tris (pH 7.5), 10 mM Na 4 P 2 O 7 , 50 mM NaF, 100 mM NaCl, 5 mM EDTA, 2 mM benzamidine, 50 g/ml leupeptin, 1 mM PMSF, and 1 mM sodium vanadate, and cleared by centrifugation at 16,000 ϫ g for 2.5 min. Detergent-solubilized lysates were separated on SDS-polyacrylamide gels, transferred onto PVDF membranes, and probed using the indicated antibody. Blots were visualized via chemiluminescence on a FluorChem imaging system (Alpha Innotech). Densitometric analyses were performed on AlphaView software (Alpha Innotech).
Immunoprecipitation-293T cells were transfected with mRFP or PKM-RFP and treated with inhibitors for 30 min in cell culture medium at 37°C. Cells were then rinsed with icecold PBS and lysed on ice in a buffer containing 1% Triton X-100, 50 mM Tris (pH 7.5), 10 mM Na 4 P 2 O 7 , 50 mM NaF, 150 mM NaCl, 5 mM EDTA, 2 mM benzamidine, 50 g/ml leupeptin, 1 mM PMSF, 1 mM sodium vanadate, and 1 M microcystin, then cleared by centrifugation at 16,000 ϫ g for 2.5 min. Detergent-solubilized lysates were precleared with Protein A/G UltraLink Resin (ThermoScientific) for 1 h at 4°C with rocking. DsRed antibody (3:1000) was then added to 1 ml of precleared lysates containing equal protein as determined by the Bradford protein assay and incubated for a total of 3 h at 4°C with rocking. Protein A/G UltraLink Resin was added to the immune complex for the last 1 h of incubation, after which samples were washed in lysis buffer and analyzed by SDS-PAGE and immunoblotting as described above.
Live Cell Fluorescence Imaging-COS-7 cells were plated onto sterilized glass coverslips in 35-mm imaging dishes and co-transfected with CKAR and either mRFP or PKM-RFP. Approximately 48 h post-transfection, the cells were washed with and subsequently imaged in Hanks' balanced salt solution (Cellgro) containing 1 mM CaCl 2 in the dark at room temperature, and the specified drugs were introduced during live cell imaging. Images were acquired via a 40ϫ objective on a Zeiss Axiovert microscope (Carl Zeiss Microimaging) using a MicroMax digital camera (Roper-Princeton Instruments) controlled by MetaFluor software version 3.0 (Universal Imaging Corp.). Optical filters were obtained from Chroma Technologies. Time-lapse images of cyan fluorescent protein (CFP), fluorescence resonance energy transfer (FRET), and yellow fluorescent protein (YFP) were collected every 15 s through a 10% neutral density filter. CFP and FRET images were obtained through a 420/20 nm excitation filter, a 450 nm dichroic mirror, and either a 475/40 nm emission filter (CFP) or a 535/25 nm emission filter (FRET). YFP images monitored as a control for photobleaching were obtained through a 495/10 nm excitation filter, a 505 nm dichroic mirror, and a 535/25 nm emission filter. Excitation and emission filters were switched in filter wheels (Lambda 10-2, Sutter). Integration times were 200 ms for CFP and FRET and 100 ms for YFP.
For each cell imaged, MetaFluor calculated a FRET ratio consisting of the average CFP/FRET for a manually selected cellular region. Base-line FRET ratios were acquired for 5 min before introduction of inhibitors, and the trace for each cell was normalized either to its average base-line value or to its minimum point. Normalized FRET ratios were combined from nՆ11 cells/group over at least three independent experiments and plotted as mean Ϯ S.E.
In Vitro Kinase Activity Assay-The effect of 1 M ZIP or scrambled ZIP on PKC activity in vitro was assayed by monitoring 32 P incorporation from [␥-32 P]ATP (3000 Ci/mmol; PerkinElmer Life Sciences) into a synthetic PKC-selective substrate peptide (Ac-FKKSFKL-NH 2 , AnaSpec) by purified PKC (Millipore) essentially as described previously (23) . Briefly, purified PKC (7 nM) was incubated with substrate peptide (100 M) in the presence of PBS vehicle control, 1 M ZIP, or 1 M scrambled ZIP in a total reaction volume of 80 l in buffer containing 16 mM HEPES (pH 7.5), 1.2 mM DTT, 1 mM EGTA (pH 7.9), 5 mM MgCl 2 , and [␥-32 P]ATP (100 M; 0.1 Ci/mmol) for 11 min at 30°C. Reactions were quenched by the addition of 25 l of a solution containing 0.1 M ATP and 0.1 M EDTA (pH 8). Aliquots (85 l) were spotted onto P81 cation-exchange chromatography paper (Whatman), washed four times with 0.4% (v/v) phosphoric acid and once with 95% ethanol, and radioactivity was determined by liquid scintillation counting. One unit is defined as 1 nmol of phosphate incorporated/min at 30°C; data are expressed as the specific activity of PKC (milliunits g
Ϫ1
) and plotted as the mean Ϯ S.E. of triplicate assays.
RESULTS

ZIP and Chelerythrine Do Not Inhibit PKM in Mammalian
Cells-We examined the effects of ZIP and chelerythrine on PKM activity in mammalian cell lines using two approaches. First, we used a Ser(P) PKC substrate antibody to detect any substrates whose phosphorylation was significantly enhanced in cells overexpressing PKM-RFP compared with cells expressing RFP alone; this antibody effectively probes PKC substrates in cells (14) . Overexpression of PKM in 293T cells robustly enhanced the phosphorylation of multiple PKC substrates, in particular of a protein with an apparent molecular mass of ϳ180 kDa (Fig. 1A ; compare lane 1 with 4 and lane 7 with 9). Cells were mock treated or treated for 1 h with 1 M either ZIP, scrambled ZIP, or chelerythrine, the inhibitor concentrations used in previous studies on LTP and the treatment duration selected based on the fact that 1 M chelerythrine had been observed to achieve full inhibition of potentiated excitatory postsynaptic currents within 10 min during whole cell The graph quantifies PKC substrate phosphorylation normalized for PKM-RFP expression and ␤-actin levels and relative to the RFP-transfected, vehicle-treated group (mean Ϯ S.E. of six independent experiments). B, COS-7 cells co-transfected with CKAR and either RFP or PKM-RFP were monitored using live cell fluorescence imaging for changes in FRET ratio in response to addition of 1 M ZIP or 1 M staurosporine. The trace for each cell imaged was normalized to its average base-line value, and normalized FRET ratios were combined from Ն11 cells/group over three independent experiments and plotted as mean Ϯ S.E. (error bars). C, in vitro activity of pure PKC (7 nM) toward a PKC-selective peptide (100 M) was measured in the presence of vehicle (PBS), 1 M ZIP, or 1 M scrambled ZIP (mean Ϯ S.E. for n ϭ 3/group). D, HeLa cells were treated with DMSO or 10 M chelerythrine for 24 h. lanes 4-6) ; nor was it affected by treatment with chelerythrine (compare lane 9 with 10). Basal phosphorylation of this substrate was also unaffected by these compounds (compare lanes 1-3, 7 with 8) . Quantitation of data from six independent experiments confirmed no significant effects of any of these compounds on the phosphorylation of this PKM substrate (Fig. 1A, graph) or any of the other substrates recognized by this antibody (data not shown). Similar results were obtained in HeLa cells (data not shown).
recordings (3). Phosphorylation of the Ser(P) substrate by recombinant PKM-RFP was not affected by treatment of cells with ZIP or scrambled ZIP (compare
In a second and independent approach, we took advantage of CKAR, a genetically encoded FRET-based reporter of PKC activity (20) , to measure the activities of endogenous PKC and overexpressed PKM-RFP in real time in live cells in response to addition of inhibitors. COS-7 cells were co-transfected with CKAR and either RFP vector control or PKM-RFP. Addition of 1 M ZIP had no effect on the base-line-normalized FRET ratio in either case and therefore inhibited neither endogenous PKCs nor overexpressed PKM (Fig. 1B) . As a positive control, staurosporine (a potent inhibitor of PKCs, see Fig. 2 ) robustly inhibited endogenous PKC activity and caused an even greater decrease in FRET ratio in the presence of overexpressed PKM (Fig. 1B ). An analogous CKAR experiment also showed that 1 M chelerythrine did not inhibit overexpressed PKM (data not shown).
The effectiveness of the ZIP and scrambled ZIP used in this study was confirmed by their inhibition of purified PKC in vitro ( Fig. 1C ; similar results were obtained in the presence of phosphatidylserine except that activity was ϳ2-fold higher). The chelerythrine used in this study was also confirmed to be biologically active, as evidenced by its ability to trigger apoptosis in HeLa (Fig. 1D ) and 293T cells (data not shown).
Staurosporine Inhibits PKM Activity in Mammalian Cells by Inhibiting Activation Loop Phosphorylation-We next tested the effects of staurosporine, a general kinase inhibitor reported not to affect LTP (3) or memory (4), on PKM activity in cells. COS-7 cells co-transfected with CKAR and either RFP or PKM-RFP were monitored for changes in FRET ratio in response to addition of staurosporine. 100 nM staurosporine, the concentration used in the studies on LTP and memory, resulted in a significant drop in CKAR phosphorylation both in control cells and those overexpressing PKM (Fig. 2A) . 100 nM staurosporine was enough to inhibit endogenous PKC activity FIGURE 2. Staurosporine inhibits PKM activity in mammalian cells by inhibiting its constitutive activation loop phosphorylation. A and B, COS-7 cells co-transfected with CKAR and either RFP or PKM-RFP were monitored using live cell fluorescence imaging for changes in FRET ratio in response to addition of (A) 100 nM staurosporine followed by a further 900 nM staurosporine or (B) 6 M bisIV followed by 100 nM staurosporine and a further 900 nM staurosporine. C, COS-7 cells co-transfected with the phosphoacceptor Thr/Ala mutant of CKAR (CKART/A) and either RFP or PKM-RFP were monitored for changes in FRET ratio in response to addition of 1 M staurosporine. For all imaging experiments in this figure, the trace for each cell imaged was normalized to its minimum value, and normalized FRET ratios were combined from Ն 13 cells/group over at least three independent experiments and plotted as mean Ϯ S.E. D, 293T cells transfected with RFP (immunoprecipitation control) or PKM-RFP were treated with vehicle, 100 nM or 1 M staurosporine, or 1 M ZIP, then lysed. DsRed antibody was used to immunoprecipitate the transfected proteins, and samples were Western blotted with an antibody specific to the phosphorylated activation loop of PKC isozymes (pAL) or with DsRed antibody. The graph quantifies activation loop phosphorylation of immunoprecipitated PKM-RFP normalized for PKM-RFP expression and relative to the vehicle-treated group (mean Ϯ S.E. (error bars) for n Ն 8/group). **, p Ͻ 0.01 and ***, p Ͻ 0.001 compared with DMSO-and 1 M ZIP-treated by Bonferroni post hoc test after one-way ANOVA.
fully, as addition of more staurosporine did not further decrease the FRET ratio of CKARϩRFP (Fig. 2A) . In contrast, this addition of another 900 nM staurosporine did cause an additional drop in the FRET ratio of CKARϩPKM-RFP, revealing inhibition of the overexpressed PKM ( Fig. 2A) . Thus, the basal activity of cellular PKM is effectively inhibited by 1 M staurosporine.
To discriminate whether 100 nM staurosporine inhibits only endogenous PKC activity or whether it also inhibits PKM activity, cells were pretreated with 6 M general PKC inhibitor bisIV to abolish endogenous PKC activity before the addition of staurosporine. 6 M bisIV completely inhibited endogenous PKC activity, as subsequent addition of 100 nM or up to 1 M staurosporine did not further decrease the FRET ratio of CKARϩRFP (Fig. 2B) . The smaller response of CKARϩPKM-RFP to bisIV compared with CKARϩRFP can be attributed to the antagonizing action of uninhibited PKM-RFP replacing phosphates on CKAR lost due to bisIV inhibition of endogenous PKCs. Importantly, the PKC activity in cells overexpressing PKM and pretreated with bisIV was additionally inhibited by 100 nM staurosporine (Fig. 2B) , revealing that this concentration of staurosporine is sufficient to inhibit PKM. Thus, the bisIV-induced drop in the CKAR FRET ratio in Fig. 2B reflects the contribution of endogenous PKC (ϳ20% of the maximal drop), and the subsequent staurosporine-induced drops reflect inhibition of overexpressed PKM. These FRET ratio changes arise from bona fide phosphorylation of CKAR at its phosphoacceptor site, as a mutant construct of CKAR with Ala at the phosphoacceptor Thr (CKART/A) showed no significant response to 1 M staurosporine (Fig. 2C ). These data establish that 100 nM staurosporine definitively inhibits the activity of PKM in cells.
Staurosporine is relatively ineffective at inhibiting PKC itself in vitro (15) . However, it binds with nanomolar affinity to and potently inhibits the upstream kinase PDK1 (10, 16) , which is required for the activation loop phosphorylation and catalytic competence of all PKC isozymes (17, 19) , including PKC (18) . Of particular relevance to this study, phosphorylation at the PDK1 site on PKC (Thr-410) is required for catalytic activity: enzyme that is not phosphorylated on Thr-410, or constructs with an Ala at this position, have no significant catalytic activity (24) . Staurosporine treatment of 293T cells overexpressing PKM caused a marked reduction (54 Ϯ 6% (100 nM), 59 Ϯ 6% (1 M); p Ͻ 0.0001, one-way ANOVA) in the activation loop phosphorylation of immunoprecipitated PKM (Fig. 2D) . Thus, staurosporine inhibits PKM activity in cells by inhibiting its activation loop phosphorylation by PDK1.
ZIP and Chelerythrine Do Not, But Staurosporine Does, Inhibit PKM in Rat Hippocampal Brain Slices-We then examined the effects of these inhibitors on PKM activity when administered in situ to organotypic hippocampal brain slices. Here, we took advantage of the high expression of the PKCspecific substrate MARK2/Par-1b (25) , whose phosphorylation in brain slices was assessed using a phosphoantibody specific to its PKC phosphorylation site (Fig. 3A) . Overexpression of PKM-RFP using Sindbis virus (21) increased the phosphorylation of MARK2 2.2 Ϯ 0.4-fold (n ϭ 15; compare lane 1 with 6). Brain slices were bath-treated with the concentrations of ZIP and chelerythrine used in previous studies on synaptic plasticity (1 M) (3) or with a 10-fold higher concentration for 4 h, long enough for ZIP and chelerythrine to have exerted their full effects on LTP when applied in bath to hippocampal slices in previous studies (3) . Indeed, ZIP and chelerythrine can disrupt hippocampal LTP maintenance in rat brain slices and in vivo in rat and mouse in as little as 2 h (26) . Quantitative analysis of multiple independent experiments revealed no inhibition by ZIP, scrambled ZIP, or chelerythrine of either endogenous kinase or overexpressed PKM (Fig. 3A, bar graph) , even at concentrations of 10 M (overexpression p Ͻ 0.001, drug p ϭ 0.90, interaction p ϭ 0.89, two-way ANOVA). In fact, peptides had a modest stimulatory effect on phosphorylation by both endogenous kinase and overexpressed PKM-RFP, indicating biological activity of the compounds in this preparation. Similar results were observed in brain slices probed with the Ser(P) PKC substrate antibody used in Fig. 1A (data not shown) .
In contrast to ZIP and chelerythrine, staurosporine inhibited the phosphorylation of MARK2 at the PKM site. Quantitative analysis of eight independent experiments revealed that 100 nM staurosporine resulted in a significant decrease in the phosphorylation of MARK2 in brain slices overexpressing PKM to 50 Ϯ 20% that observed in mock-treated samples (Fig. 3B) . Taken together, these data establish in hippocampal brain slices that ZIP and chelerythrine do not inhibit PKM but that staurosporine does via its potent inhibition of the upstream kinase PDK1.
DISCUSSION
Identification of the molecules responsible for the long lasting maintenance of memory continues to be an important biological question. A number of recent studies have used pharmacological approaches to implicate the action of PKM as a potential mechanism (3-7). To our knowledge, the effectiveness of ZIP, chelerythrine, or staurosporine in inhibiting PKM within the complex milieu of mammalian cells and tissues has not been previously demonstrated. Here, we find that ZIP and chelerythrine fail to inhibit PKM activity in heterologous cells or brain slices. Based on the oriented peptide library work of Cantley and co-workers (27) , the sequences of ZIP (SIYRR-GARRWRKL), which is identical to that of the PKC pseudosubstrate, and scrambled ZIP (RLYRKRIWRSAGR), when substituted with Ser at the phosphoacceptor position (underlined), are predicted to be equally good substrates for PKC, which may explain the partial inhibition of PKC in vitro even by scrambled ZIP (Fig. 1C) , a negative control peptide. Furthermore, the pseudosubstrate sequence of PKC, when substituted with Ser at the phosphoacceptor site, is actually phosphorylated with an order of magnitude lower K m and an order of magnitude higher V max /K m by a different PKC isozyme, PKC␦ (27) . Thus, the lack of a defined substrate consensus sequence for PKC isozymes, including PKC, precludes the use of pseudosubstrate peptides as specific pharmacological tools. Because ZIP clearly affects LTP, we conclude that this basic peptide likely disrupts a macromolecular interaction in cells via a target unrelated to PKM. Finally, we find that staurosporine actually does inhibit PKM in cells and brain slices by inhibiting its constitutive phosphorylation by the upstream kinase PDK1. This effect of staurosporine would be overlooked in in vitro assays, from which PDK1 would be absent, because the purified PKM used would already be phosphorylated at the PDK1 site and thus catalytically competent.
Measurement of the phosphorylation of multiple distinct endogenous PKM substrates in cell lines and hippocampal brain slices as well as an overexpressed PKM substrate in the form of CKAR all show that, in contrast to their effects in vitro, ZIP and chelerythrine do not and staurosporine actually does inhibit PKM in the complex milieu of mammalian cells and tissues. The inconsistencies between the effectiveness of ZIP, chelerythrine, and staurosporine in inhibiting PKM activity in cells and tissues and their reported effects on learning and memory provide a double dissociation between PKM activity and synaptic plasticity. We note that genetic studies in which PKM has been overexpressed have been used to support a role for PKM in memory (3, 28) . Given that overexpressed kinases can mislocalize and increase the phosphorylation of both specific and nonspecific substrates in cells and given that these reports have not included specificity controls, their results are inconclusive. Because the cellular pharmacology of PKM contrasts with its in vitro profile, we conclude that PKM cannot be implicated as the molecular substrate of long term plasticity or memory based on the prevalent studies using the pharmacological tools of ZIP, chelerythrine, and staurosporine.
